# Placebo-controlled, Proof-of-concept Study to Evaluate the Safety and Efficacy of Lanifibranor Alone and in Combination With SGLT2 Inhibitor EmpaGliflozin in patiEnts With NASH and Type 2 Diabetes Mellitus

> **NCT05232071** · PHASE2 · COMPLETED · sponsor: **Inventiva Pharma** · enrollment: 42 (actual)

## Conditions studied

- NASH - Nonalcoholic Steatohepatitis
- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** IVA337
- **DRUG:** Placebo
- **DRUG:** Empagliflozin

## Key facts

- **NCT ID:** NCT05232071
- **Lead sponsor:** Inventiva Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-06-29
- **Primary completion:** 2024-03-30
- **Final completion:** 2024-06-04
- **Target enrollment:** 42 (ACTUAL)
- **Last updated:** 2024-07-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05232071

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05232071, "Placebo-controlled, Proof-of-concept Study to Evaluate the Safety and Efficacy of Lanifibranor Alone and in Combination With SGLT2 Inhibitor EmpaGliflozin in patiEnts With NASH and Type 2 Diabetes Mellitus". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05232071. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*